OncoMatch/Clinical Trials/NCT06118762
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
Is NCT06118762 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Fruquintinib for metastatic colorectal cancer.
Treatment: Fruquintinib — To evaluate the efficacy and safety of Fruquintinib combined with Raltitrexed in the treatment of metastatic colorectal cancer that progressed or could not be tolerated after previous fluorouracil, oxaliplatin, and irinotecan based therapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: fluorouracil
The patient progressed or was intolerant after receiving at least previous standard therapy containing fluorouracil, oxaliplatin, and irinotecan.
Must have received: oxaliplatin
The patient progressed or was intolerant after receiving at least previous standard therapy containing fluorouracil, oxaliplatin, and irinotecan.
Must have received: irinotecan
The patient progressed or was intolerant after receiving at least previous standard therapy containing fluorouracil, oxaliplatin, and irinotecan.
Cannot have received: VEGFR inhibitor (Fruquintinib, Apatinib, Regorafenib, Anlotinib)
Previous treatment with Fruquintinib or other anti-vascular endothelial growth factor receptor (VEGFR) inhibitors such as Apatinib, Regorafenib, and Anlotinib
Cannot have received: antifolate (Raltitrexed)
Previous treatment with Raltitrexed
Cannot have received: systemic anti-tumor therapy
Exception: within four weeks prior to enrollment
received other systemic anti-tumor therapy, including chemotherapy, signal transduction inhibitors, hormone therapy, and immunotherapy within four weeks prior to enrollment
Lab requirements
Blood counts
Absolute neutrophil count ≥1.5×10^9/L; Platelet ≥80×10^9/L; Hemoglobin ≥8g/dL
Kidney function
Serum creatinine ≤1 × ULN; endogenous creatinine clearance > 50ml/min
Liver function
Total bilirubin < 1.5 × ULN; ALT and AST < 2.5 × ULN (< 5 × ULN in patients with liver metastasis)
The functions of vital organs during the first 14 days of enrollment meet the following requirements (the use of any blood components and cell growth factors during the first 14 days of enrollment is not allowed): Absolute neutrophil count ≥1.5×10^9/L; Platelet ≥80×10^9/L; Hemoglobin ≥8g/dL; Total bilirubin < 1.5 × ULN; ALT and AST < 2.5 × ULN (< 5 × ULN in patients with liver metastasis); Serum creatinine ≤1 × ULN; endogenous creatinine clearance > 50ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify